Who
Jesus B. Mantas
Director
Company insider
Files Form 4 as: Director, Biogen; Director, International Flavors & Fragrances.
In numbers
- Trades disclosed
- 17
- Buys
- 1
- Sells
- 0
- Bought
- $240K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 19 Jun 2019
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —1,505 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —1,505 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | IFF International Flavors & Fragrancesoption or derivative · Chemicals | SEC FORM 4 Code D | —2,281 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | IFF International Flavors & Fragrancesoption or derivative · Chemicals | SEC FORM 4 Code A | —2,281 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | IFF International Flavors & Fragrancesoption or derivative · Chemicals | SEC FORM 4 Code D | —2,281 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | IFF International Flavors & Fragrancesoption or derivative · Chemicals | SEC FORM 4 Code A | —2,281 at $0.00 | filing |
| 29 Apr 2026filed 30 Apr 2026 | IFF International Flavors & Fragrancesoption or derivative · Chemicals | SEC FORM 4 Code A | —2,903 at $0.00 | filing |
| 29 Apr 2026filed 30 Apr 2026 | IFF International Flavors & Fragrancesoption or derivative · Chemicals | SEC FORM 4 Code A | —2,903 at $0.00 | filing |
| 2 Sep 2025filed 3 Sep 2025 | IFF International Flavors & Fragrancesoption or derivative · Chemicals | SEC FORM 4 Code A | —2,281 at $0.00 | filing |
| 17 Jun 2025filed 18 Jun 2025 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —2,370 at $0.00 | filing |
| 21 Jun 2024filed 25 Jun 2024 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —1,340 at $0.00 | filing |
| 26 Jun 2023filed 28 Jun 2023 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —960 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —1,370 at $0.00 | filing |
| 1 Jul 2021filed 2 Jul 2021 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —775 at $0.00 | filing |
| 9 Feb 2021filed 10 Feb 2021 | BIIB BiogenBiotechnology | SEC FORM 4 Bought | $240K898 at $267.00 | filing |
| 3 Jun 2020filed 5 Jun 2020 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —890 at $0.00 | filing |
| 19 Jun 2019filed 20 Jun 2019 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —1,155 at $0.00 | filing |
News
Biogen (NASDAQ:BIIB) Hits New 52-Week High Following Analyst UpgradeBIIB · dailypolitical.com · 14 Oct 2026Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?BIIB · insidermonkey.com · 13 Oct 2026Biogen (NASDAQ:BIIB) Stock Price Target Cut by Royal Bank Of CanadaBIIB · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Jesus B. Mantas; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.